pyrazines has been researched along with pemetrexed in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (50.00) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dubey, S; Schiller, JH | 1 |
| Masuda, N; Yanase, N; Yokoba, M | 1 |
| Lilenbaum, R; Raez, LE | 1 |
| Fenk, R; Garcia-Pardillos, G; Haas, R; Kronenwett, R; Meier, A; Neukirchen, J; Rohr, UP; Rohrbeck, A; Steidl, U | 1 |
| Bueno, R; Gordon, GJ; Kindler, HL; Mani, M; Maulik, G; Mukhopadhyay, L; Salgia, R; Sugarbaker, DJ; Yeap, BY | 1 |
| Beckett, LA; Christensen, S; Davies, AM; Gandara, DR; Ho, C; Lara, PN; Lau, DH; Metzger, AS; Tanaka, M | 1 |
| Biesma, B; Bosquée, L; Chan, KC; De Marinis, F; Gans, S; Germonpré, P; Gervais, R; Lee, JS; Makhson, A; Manikhas, G; Morgan, B; Park, K; Planchard, D; Ramlau, R; Reck, M; Scagliotti, GV; Szczesna, A; Vansteenkiste, J; von Pawel, J; Zhu, Y | 1 |
| Anthony, SP; Donehower, RC; Hurt, K; Hynes, SM; Iyengar, T; Lewandowski, K; McKane, S; Ramanathan, RK; Weiss, GJ; Westin, E | 1 |
| Barbone, D; Battula, S; Broaddus, VC; Bueno, R; Busacca, S; Cheung, P; Fennell, DA; Gray, SG; Longley, DB; Sugarbaker, DJ | 1 |
| Dobra, K; Hjerpe, A; Mundt, F; Nilsonne, G; Souri, P; Szulkin, A; Wasik, AM | 1 |
| Barnard, D; Calles, A; Calvo, E; Chen, VJ; Diaz, HB; Dickgreber, N; Huber, L; Hynes, SM; Iversen, P; Kays, L; Kumm, E; Lin, AB; Marshall, M; Merzoug, FF; Ohnmacht, U; Sebastian, M; Voss, B; Wehler, T | 1 |
| Boyd, TE; Hynes, SM; Kang, JH; Kim, SW; Lin, AB; Lin, J; Myrand, SP; Novello, S; Park, K; Pinder-Schenck, M; Richards, DA; Rosenberg, R; Scagliotti, G; Smith, D; Smyth, EN; Su, WC; Wijayawardana, S | 1 |
3 review(s) available for pyrazines and pemetrexed
| Article | Year |
|---|---|
Three emerging new drugs for NSCLC: pemetrexed, bortezomib, and cetuximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Glutamates; Guanine; Humans; Lung Neoplasms; Medical Oncology; Pemetrexed; Pyrazines | 2005 |
[New anti-cancer agents--from cytotoxic systemic chemotherapy to target-based agents].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Furans; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Oxonic Acid; Pemetrexed; Pyrazines; Pyridines; Quinazolines; Tegafur; Vinblastine; Vinorelbine | 2005 |
New developments in chemotherapy for advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Epothilones; Glutamates; Glutathione; Guanine; Humans; Lung Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pemetrexed; Pyrazines | 2006 |
5 trial(s) available for pyrazines and pemetrexed
| Article | Year |
|---|---|
Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Pemetrexed; Pyrazines; Survival Analysis | 2007 |
A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Therapy, Combination; Dyspnea; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Pemetrexed; Pyrazines; Survival Analysis; Thrombocytopenia | 2010 |
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Female; Glutamates; Guanine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pemetrexed; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyrazines | 2013 |
Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cisplatin; DNA; Female; Glutamates; Guanine; Humans; Male; Mice, Nude; Middle Aged; Neoplasms; Pemetrexed; Phenylurea Compounds; Pyrazines; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Checkpoint Kinase 1; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Treatment Outcome; Tumor Suppressor Protein p53 | 2016 |
4 other study(ies) available for pyrazines and pemetrexed
| Article | Year |
|---|---|
The proteasome inhibitor bortezomib acts differently in combination with p53 gene transfer or cytotoxic chemotherapy on NSCLC cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Genes, p53; Genetic Therapy; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Taxoids; Transfection; Tumor Cells, Cultured | 2007 |
Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Evaluation, Preclinical; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Genes, Intracisternal A-Particle; Glutamates; Guanine; Humans; Mesothelioma; Neoplasm Proteins; Pemetrexed; Pleural Neoplasms; Proteasome Inhibitors; Pyrazines; Survival Analysis | 2008 |
Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expression.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Boronic Acids; Bortezomib; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Hydroxamic Acids; Membrane Proteins; Mesothelioma; Myeloid Cell Leukemia Sequence 1 Protein; Pemetrexed; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Spheroids, Cellular; Up-Regulation; Vorinostat | 2012 |
Variation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapy.
Topics: Amino Acid Transport System y+; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Multidrug Resistance-Associated Proteins; Pemetrexed; Pyrazines; Selenious Acid | 2013 |